Be Bio (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- October 24, 2024
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
- $82,000,000
Company Info
- Traction
- Be Bio has received FDA orphan drug designation and fast track status for BE-101, and has initiated a Phase I/II trial to evaluate its safety and efficacy.
- Company Description
- Be Bio is a biopharmaceutical company focused on developing gene therapies for hemophilia B and other rare diseases. Its lead candidate, BE-101, is designed to provide a durable replacement therapy for patients with hemophilia B by inserting the human Factor IX gene into primary human B cells.
- Market
- Gene Therapy
- Coinvestors
- Bristol Myers Squibb, Takeda Ventures, ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund